Memorial Şişli Hospital
| トルコ | オーストリア | スペイン | |
| 神経芽細胞腫の複雑治療 | から $28,000 | から $180,000 | から $70,000 |
Dr. Hilmi Apak is a respected pediatric hematology-oncology specialist with more than 21 years of experience. He is trained in pediatric oncology. Dr. Apak has led advanced treatments, including bone marrow transplantation, leukemia chemotherapy, and CAR T-cell therapy.
He has published 75 international medical articles, showing his strong contribution to pediatric oncology research. Dr. Apak has worked as assistant editor for the Turkish Pediatrics Archives Periodical. He has also held important academic and leadership positions, such as Head of Pediatric Hematology-Oncology at Istanbul University-Cerrahpaşa.
Dr. Metin Demirkaya is a specialist in Pediatric Oncology. He earned his medical degree from Istanbul University Cerrahpaşa School of Medicine between 1993 and 1999. He completed his Pediatrics residency and Pediatric Oncology residency at Bursa Uludag University from 1999 to 2010.
Dr. Demirkaya has worked at leading centers such as GATA Pediatric Hematology-Oncology-Bone Marrow Transplantation Centre and Istanbul Kanuni Sultan Süleyman Education and Research Hospital. He became an Assistant Professor in 2013. In 2019, he was appointed Professor of Medicine in Pediatric Oncology at Medicana Bursa Hospital.
Dr. Demirkaya is known for his clinical skills and leadership in pediatric cancer care and bone marrow transplantation. He has made important contributions to research and has received recognition in his field.
Neuroblastoma treatment in Turkey follows a risk-adapted multimodal approach combining surgery, chemotherapy, and advanced biological therapies. Protocols are standardized by the Turkish Pediatric Oncology Group (TPOG) and the Children's Oncology Group (COG). High-risk cases often involve autologous stem cell transplantation and targeted MIBG therapy in JCI-accredited facilities.
Bookimed Expert Insight: Turkish oncology centers offer a significant efficiency advantage for international families. While European programs often have strict intake windows, private institutions like Memorial Şişli provide immediate access to TPOG 2020 protocols. These centers maintain 90% success rates for complex pediatric transplants, matching American standards at a fraction of the cost.
Patient Consensus: Parents emphasize that early risk stratification via MYCN testing was vital for choosing between observation and aggressive surgery. Many noted that post-treatment MIBG scans provided essential peace of mind for monitoring potential relapses.
Turkish hospitals such as Memorial Şişli, Medipol Mega, and Hisar Intercontinental are leading centers for neuroblastoma treatment. These JCI-accredited facilities provide advanced pediatric oncology care, including autologous stem cell transplants, immunotherapy, and targeted radiotherapy, often at costs 77% lower than US averages.
Bookimed Expert Insight: While many families focus on hospital brands, the real differentiator in Turkey is the volume of bone marrow transplants performed. Medipol Mega and Emsey Hospital manage significantly higher pediatric bed capacities than many European centers. This high volume often translates to more refined nursing protocols for managing post-transplant complications in children.
Patient Consensus: Families often emphasize the importance of requesting specific international protocols like SIOPEN. They recommend securing a second opinion from European experts before finalizing the surgical approach in Istanbul.
Parents should ask about their child's specific risk group, MYCN gene status, and the multi-phase treatment plan. Essential queries include the integration of high-intensity chemotherapy, surgery, and immunotherapy. Confirm if the clinic follows international COG or SIOP protocols to ensure standardized, high-quality pediatric oncological care.
Bookimed Expert Insight: While many search for the lowest price, the real value in Turkey lies in multidisciplinary tumor boards. Clinics like Memorial Şişli Hospital or Medipol Mega utilize 400+ specialists to review complex cases. This collaborative approach often mirrors top US centers but at 77% lower costs. Always verify if your surgeon works specifically within a dedicated pediatric oncology department rather than a general surgical unit.
Patient Consensus: Families emphasize the importance of requesting written treatment protocols and independent pathology reviews early on. They recommend confirming long-term survivorship plans, including cardiac and endocrine monitoring, before the first cycle of chemotherapy begins.
Families should plan for a 6-week to 6-month stay in Turkey for intensive neuroblastoma treatment phases. While initial diagnostics take 2–4 days, complex protocols involving surgery, chemotherapy, and stem cell transplants often require 4–7 months of local residency for monitoring.
Bookimed Expert Insight: Data from top-tier centers like Memorial Şişli and Medipol show that stay durations vary by infrastructure. Medipol features a massive 810-bed capacity, often streamlining the transition between chemotherapy and surgery. Families can often reduce total time by coordinating the 5-day chemotherapy hospitalizations with local outpatient housing.
Patient Consensus: Most families recommend budgeting 4–6 months minimum to account for recovery buffers. They suggest extending tourist visas early to avoid stress during intensive 6-week transplant isolation periods.